Posted by Michael Wonder on 12 Apr 2022
NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance
12 April 2022 - Two new antimicrobial drugs - cefiderocol and ceftazidime–avibactam - are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE today published draft guidance estimating their value to the NHS.
The NICE evaluations of cefiderocol and ceftazidime–avibactam form part of a project with NHS England and NHS Improvement and the Department of Health and Social Care that aims to incentivise research into and development of antimicrobials by testing new approaches to evaluating and paying for them.
